Clinical Trial Detail

Study of TJ011133 Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma

Complete title: A Phase 1 Study of TJ011133 Administered Alone or in Combination with

Pembrolizumab or Rituximab in Subjects with Relapsed/Refractory Advanced Solid Tumors and Lymphoma

Research Study Number	RG1005590
Principal Investigator	Ajay Gopal, MD
Phase	I

Look up trial at NIH

Research Study Description

The purpose of this study is to assess the safety and tolerability of TJ011133 in participants with solid tumors and lymphoma.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above **

Other eligibility criteria may apply.

Research Study Number

RG1005590

Keywords: Lymphoma; Solid Tumors

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

Talk to your health care providers first before making decisions about your health care.

Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

RSS feed

Last Modified, June 25, 2019